News

Amneal Announces Positive Topline Results from Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations

(August 25, 2021) – Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced positive results from the Phase 3 RISE-PD clinical trial that evaluated the novel formulation, IPX-203, in patients with Parkinson’s disease (PD) who have motor fluctuations. The trial demonstrated superior “Good On” time at the conclusion of a 13-week double-blind treatment period. Amneal plans to submit a New Drug Application (NDA) for IPX-203 with the U.S. Food and Drug Administration (FDA) in mid-2022. Click here to learn more about Amneal and IPX-203.

Follow Us Follow us on TwitterFollow us on FacebookInstagram

Sign Up for Email Alerts

By providing your email you agree to receive periodic emails from The Parkinson Alliance.

Please tell us more about yourself:

This month is? (Anti-Spam)

Contact UsTerms Of UsePrivacy Policy

The Parkinson Alliance is a nonprofit, tax-exempt charitable organization under section 501(c)(3) of the Internal Revenue Code. Donations are tax-deductible as allowed by law. Copyright © 2020 The Parkinson Alliance. All rights reserved.